Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

References

Page 1

	Year	Citations
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients New England Journal of Medicine	2000	8.6K
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw, New England Journal of Medicine	2001	7.4K
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke, New England Journal of Medicine	2001	5.9K
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lennart Hansson, Alberto Zanchetti, S. George Carruthers, The Lancet ThrombosisHypertensionHypertension Optimal TreatmentNon-pharmacological InterventionCardiovascular Disease	1998	5.8K
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Björn Dahlöf, Richard B. Devereux, Sverre E. Kjeldsen, The Lancet HypertensionCardiovascular DiseaseEndpoint ReductionRandomised TrialAntihypertensive Therapy	2002	5.4K
Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial Jeremiah Stamler, Olga Vaccaro, James D. Neaton, Diabetes Care	1993	4.1K
1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension Guidelines Subcommittee Journal of Hypertension HypertensionGuidelines SubcommitteeHypertension GuidelinesPreventive CardiologyBlood Pressure	1999	3.7K
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy The Lancet Metabolic SyndromeHypertensionDiabetes ManagementCardiovascular DiseaseHope Study	2000	3.2K
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Jfe Mann, Hertzel C. Gerstein, Salim Yusuf PubMed	2000	2.1K
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lennart Hansson, Lars Lindholm, Leo Niskanen, The Lancet HypertensionCardiovascular DiseaseAntihypertensive AgentsMedicineAntihypertensive Therapy	1999	2K

Page 1